For the Inventor, By the Inventor

Enter assignee name

Bothell, WA, United States of America

Seattle Genetics, Inc.

USPTO Granted Patents = 132

% Expired Patents = 8.3

CIPO Patents = 15

EPO Patents = 58

Trademarks = 15

Forward Citations = 4,549

Loading Chart...

Loading Chart...

105 inventors (with patents filed for the assignee):

Peter Senter (30 out of 47 patents)

Svetlana Doronina (28 out of 32 patents)

Scott C Jeffrey (26 out of 30 patents)

4. Brian E Toki (24 out of 25 patents)

5. Patrick J Burke (19 out of 26 patents)

6. Alan F Wahl (19 out of 19 patents)

7. Che-Leung Law (15 out of 20 patents)

8. Django Sussman (13 out of 20 patents)

9. Dennis R Benjamin (13 out of 24 patents)

10. Philip Wilson Howard (12 out of 92 patents)

11. Paul J Carter (12 out of 58 patents)

12. Toni Beth Kline (11 out of 22 patents)

13. Charlotte McDonagh (10 out of 13 patents)

14. Julie A McEarchern (10 out of 13 patents)

15. Eric Sievers (9 out of 16 patents)

Core Competencies:

Antibody Drug Conjugates

Anti-CD30

Pyrrolobenzodiazepines

Cancer Treatment

Monomethylvaline

CD33 Antibodies

CD19 Binding Agents

Core Fucosylation

Humanized Antibodies

Conjugation Methods

Auristatin Derivatives

Targeted Conjugates

132 patents: Sort by Forward Citations

1. 11795229 - Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy (2023-10-24),

2. 11299543 - Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment (2022-04-12),

3. 10912842 - CD123 antibodies and conjugates thereof (2021-02-09),

4. 10828375 - Distribution of engineered-cysteine caps (2020-11-10),

5. 10808039 - Monomethylvaline compounds capable of conjugation to ligands (2020-10-20),

6. 10787514 - CD33 antibodies and use of same to treat cancer (2020-09-29),

7. 10722592 - CD48 antibodies and conjugates thereof (2020-07-28),

8. 10722549 - Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates (2020-07-28),

9. 10669348 - Antibody drug conjugates (ADC) that bind to 158P1D7 proteins (2020-06-02),

10. 10561739 - Targeted pyrrolobenzodiazapine conjugates (2020-02-18),

11. 10478469 - Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates (2019-11-19),

12. 10464997 - Selective reduction of proteins (2019-11-05),

13. 10457976 - Preparing antibodies from CHO cell cultures for conjugation (2019-10-29),

14. 10444241 - Detection and treatment of CD30cancers (2019-10-15),

15. 10443035 - Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation (2019-10-15),

Company Overview

Seattle Genetics, Inc., based in Bothell, WA, specializes in the development of innovative antibody-drug conjugates (ADCs) for cancer treatment. The company focuses on harnessing the power of targeted therapies, particularly through its expertise in anti-CD30 and CD33 antibodies, as well as CD19 binding agents. Seattle Genetics is at the forefront of advancing cancer therapeutics, utilizing technologies such as pyrrolobenzodiazepines and core fucosylation to enhance treatment efficacy and improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

132 Patents

#3 in Bothell, WA

#54 in Washington

#2,942 in US

#6,098 in the World

Bothell, WA, United States of America

Seattle Genetics, Inc.

Forward Citations = 4,549

105 inventors:

Peter Senter (30 out of 47 patents)

Svetlana Doronina (28 out of 32 patents)

Scott C Jeffrey (26 out of 30 patents)

4. Brian E Toki (24 out of 25 patents)

5. Patrick J Burke (19 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Seattle Genetics, Inc.. Retrieved from https://idiyas.com/company/seattle-genetics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…